Bone densitometry as an adjunct to GnRH agonist therapy

Area of Science:

• Endocrinology
• Bone Physiology
• Medical Imaging

Background:

• Gonadotropin releasing hormone (GnRH) agonists are used to treat conditions like endometriosis.
• GnRH agonist therapy can lead to estrogen deficiency, impacting bone health.
• Bone densitometry use during clinical trials has yielded varied conclusions regarding skeletal effects.

Purpose of the Study:

• To establish optimal bone densitometry protocols for women undergoing GnRH agonist therapy.
• To provide guidance on when and how to use bone densitometry methods.
• To ensure proper interpretation of bone density results in this patient population.

Main Methods:

• Literature review of bone densitometry studies in women on GnRH agonists.
• Analysis considering bone physiology and different densitometry device measurements.
• Development of a framework for patient assessment and monitoring.

Main Results:

• Most women on GnRH agonists experience transient bone density decrease due to estrogen deficiency.
• Bone density is typically regained after treatment cessation, though recovery may take years.
• Women with pre-existing low bone density are at higher risk of fracture and require careful monitoring.

Conclusions:

• Bone densitometry methods provide different information and require proper interpretation.
• Peripheral bone measurements can assess baseline status, but spinal measurements are crucial for monitoring GnRH agonist effects.
• Spinal bone densitometry offers sufficient sensitivity to track skeletal changes during and after GnRH agonist therapy.